Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Overview
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Companies Involved in Therapeutics Development
Clayton Biotechnologies Inc
Derm-Biome Pharmaceuticals Inc
Histogen Inc
Takeda Pharmaceutical Co Ltd
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Drug Profiles
BaxB-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DB-207 - Drug Profile
Product Description
Mechanism Of Action
History of Events
emricasan - Drug Profile
Product Description
Mechanism Of Action
History of Events
emricasan - Drug Profile
Product Description
Mechanism Of Action
Fusion Protein to Activate Caspases for Age Related Macular Degeneration, Diabetic Retinopathy and Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Dormant Products
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Discontinued Products
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Product Development Milestones
Featured News & Press Releases
Nov 02, 2021: Histogen and Amerimmune announce the presentation of Emricasan data in COVID-19 at the American College of Allergy, Asthma, and Immunology Conference
Sep 16, 2021: Derm-Biome Pharmaceuticals reports positive results from a preclinical study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole
Aug 17, 2021: Histogen-Amerimmune’s drug shows effectiveness against Covid-19
Jun 23, 2021: Histogen-Amerimmune’s emricasan yields positive results in Covid-19 trial
May 19, 2021: Histogen and Amerimmune report publication on Emricasan in COVID-19
Mar 16, 2021: Histogen and Amerimmune announce first patient dosed in phase 1 study of Emricasan in symptomatic COVID-19 patients
Oct 06, 2020: Derm-Biome Pharmaceuticals reports positive results from a preclinical study in psoriasis
Jun 24, 2019: Cotus announces results from ENCORE-LF and ENCORE-PH phase 2b clinical trials in SH Cirrhosis
Jun 24, 2019: Novartis provides update on phase 2b ENCORE-LF trial in SH cirrhosis
Apr 30, 2019: Cotus Pharmaceuticals announces publication demonstrating that Emricasan Ameliorates Portal Hypertension, improves liver structure and function in a preclinical model of advanced cirrhosis
Apr 15, 2019: Cotus late-breaker oral presentation at EASL meeting details results of ENCORE-PH phase 2b clinical trial in patients with SH cirrhosis and severe portal hypertension
Mar 21, 2019: Cotus announces top-line results from ENCORE-NF phase 2b clinical trial in SH fibrosis
Mar 13, 2019: Cotus Late-breaker oral presentation at EASL meeting to detail results of ENCORE-PH Phase 2b clinical trial in patients with SH Cirrhosis and Severe Portal Hypertension
Feb 12, 2019: Cotus announces completion of enrollment in ENCORE-LF phase 2b clinical trial of Emricasan in patients with decompensated SH cirrhosis
Jan 28, 2019: Cotus Pharmaceuticals announces publications expanding on previously reported results from completed phase 2 FLD-SH, portal hypertension and liver cirrhosis clinical trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Clayton Biotechnologies Inc, 2022
Pipeline by Derm-Biome Pharmaceuticals Inc, 2022
Pipeline by Histogen Inc, 2022
Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022